Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
An erratum to this article was published (JAMA, 20 Aug 2024 ↗)
Authors' conclusion
In Chinese adults with obesity or overweight, once-weekly treatment with tirzepatide 10 mg or 15 mg resulted in statistically significant and clinically meaningful weight reduction with an acceptable safety profile.
Study context
- Population
- Chinese adults (≥18 years) with body mass index (BMI) ≥28, or ≥24 with ≥1 weight-related comorbidity, excluding diabetes; 29 centers in China, September 2021 to December 2022201 completed
- Participants
- 210 adults
- Comparison
- Once-weekly SC tirzepatide 10 mg or 15 mg vs placebo, plus lifestyle intervention, for 52 weeks
- Tirzepatide 10 mgn = 70
- Tirzepatide 15 mgn = 71
- Placebon = 69reference
- Primary endpoint
- Co-primary: percent change in body weight from baseline and weight reduction of ≥5%
- Follow-up
- Week 52
Methodological detailsdouble-blind, placebo-controlled, phase 3, multicentre (29 centers in China)
- Double-blind
- Placebo-controlled
- Phase 3
- Multicentre (29 centers in China)
Primary result
As reported in the abstract
Mean change in body weight
Tirzepatide 10 mg
−13.6%
mean · 95% CI −15.8%–-11.4%
Tirzepatide 15 mg
−17.5%
mean · 95% CI −19.7%–-15.3%
Placebo
−2.3%
mean
Each group vs placeboDifference (95% CI)P value
Tirzepatide 10 mg
−11.3%(−14.3% to −8.3%)
P < 0.001Tirzepatide 15 mg
−15.1%(−18.2% to −12.1%)
P < 0.001Further findings
Co-primary: body weight reduction ≥5% · week 52 — Tirzepatide 10 mg vs Placebo · intention-to-treat
P < 0.001 for comparisons with placebo
| Outcome | P value |
|---|---|
| Co-primary: body weight reduction ≥5% · week 52Tirzepatide 15 mg vs Placebo · intention-to-treat | P < 0.001 for comparisons with placebo |
Safety
Treatment-emergent adverse events
- Events leading to treatment discontinuation
- <5%
- Most frequent TEAEs with tirzepatide were gastrointestinal, mostly mild to moderate
Original publication
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. Published 20 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →